Evidence of hypoglycemic anhedonia and modulation by bupropion in rats

Horman, Thomas; Ayoub, Samantha M.; Leri, Francesco

doi:10.1016/j.pbb.2021.173120

Cited by 1 publication

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with the comorbidity between MDD and type 2 diabetes (Kullmann et al, 2016), lower insulin sensitivity and higher fasting glucose levels were strongly associated with anhedonia. Likewise, hyperglycemia, diet-induced changes in insulin signaling, and knockout of insulin receptors facilitate depression and anhedonia-like behavior in rodents (Aswar et al, 2017; Dutheil et al, 2016; Horman et al, 2021; Kleinridders et al, 2015). However, we did not observe altered metabolic hormone concentrations in MDD compared to HCPs when adjusted for age, sex, and BMI; only higher glucose levels were found in MDD, supporting that primarily the anhedonic subtype of MDD is associated with metabolic dysregulation (Moreira et al, 2019; Willame et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

Blunted anticipation but not consummation of food rewards in depression

Schulz,

Klaus,

Peglow

et al. 2024

Preprint

View full text Add to dashboard Cite

Anhedonia is a core symptom of major depressive disorder (MDD) and is associated with worse treatment outcomes. While its narrow definition as a hedonic or consummatory deficit evolved to encompass anticipatory and motivational reward facets, it remains unclear where reward deficits manifest. Since evidence that metabolic hormones influence reward processing accumulates, investigating their role in alleviating reward deficits may provide crucial insights. To address these gaps, we conducted a study with 103 participants, including 52 patients with MDD and 51 healthy control participants (HCPs). After overnight fasting, blood samples were collected to determine the concentration of ghrelin, glucose, insulin, and triglycerides in serum/plasma. Participants then completed a taste test with repeated ratings of wanting and liking for snacks before and after tasting, allowing to gradually move from reward anticipation to consummation. Patients with MDD showed decreased wanting (p = .046) but not liking for food rewards during visual anticipation. However, these group differences disappeared once patients inspected and tasted the food as patients increased wanting relative to HCPs (p = .004), providing strong evidence against the hypothesis of a consummatory deficit (Bayes Factors > 9). In contrast to a narrow definition of anhedonia, higher scores on the Snaith-Hamilton Pleasure Scale (SHAPS) were more strongly associated with reduced anticipatory food wanting (p = .010), not liking, and more pronounced increases in wanting with reward proximity (p = .037). Across groups and phases, acyl ghrelin was associated with higher wanting and liking ratings, while poor glycemic control was associated with anhedonia. Overall, our study demonstrates that MDD and its cardinal symptom, anhedonia, are associated with a reduced anticipation of rewards rather than an impaired ability to experience pleasure. Since ghrelin was associated with elevated reward ratings, targeting the gut-brain axis could be a promising avenue for treating reward deficits.

show abstract